Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Conclusion: Systemic Mastocytosis is a rare disease with variable manifestations and outcome. Nowadays, several therapeutic modalities are available for effective disease management over time. Novel targeted therapies seem to be promising to further improve the outcome, but still early and accurate diagnosis, in accordance to WHO classification, remains important.Table 1.DisclosuresGavriilaki: European Hematology Association: Research Funding. Terpos: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grant, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grant, Patents & Royalties; Genesis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grant, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grant, Patents & Royalties; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Tsonis, I., Kanellias, N., Lazaris, V., Panayiotidis, P., Sotiropoulos, D., Vassilakopoulos, T., Arapidou, Z., Eleutherakis-Papaiakovou, E., Boutsis, D., Galanopoulos, A., Kotsianidis, I., Kyrtsonis, M.-C., Leonidopoulou, T., Pangalis, G., Papaioannou, M. Tags: 634. Myeloproliferative Syndromes: Clinical Source Type: research